Leukocyte Integrin Mac-1 Promotes Acute Cardiac Allograft Rejection

Koichi Shimizu, MD, PhD; Peter Libby, MD; Rica Shubiki, BA; Masashi Sakuma, MD; Yunmei Wang, PhD; Kenichi Asano, MD, PhD; Richard N. Mitchell, MD, PhD*; Daniel I. Simon, MD, PhD*

Background—In allograft rejection, recipient leukocytes and alloantibodies first target donor endothelial cells. Although the leukocyte integrin Mac-1 (αMβ2, CD11b/CD18) facilitates cell–cell interactions among leukocytes and interactions between leukocytes and endothelial cells or platelets, its role in allograft survival and vasculopathy is incompletely defined.

Methods and Results—This study examined parenchymal rejection and graft arterial disease after total allomismatched cardiac transplantation (BALB/c donor heart and B6 recipients) in wild-type (WT) and Mac-1-deficient (Mac-1−/−) recipients. Recipient Mac-1 deficiency attenuated parenchymal rejection and significantly prolonged cardiac allograft survival from 8.3±1.3 days in WT recipient allografts (n=18) to 13.8±2.3 days in Mac-1−/− recipient allografts (n=6; P<0.0001). Accumulation of neutrophils and macrophages significantly decreased in Mac-1−/− compared with WT recipients. Adoptive transfer of WT but not Mac-1−/− macrophages to Mac-1−/− recipients exacerbated parenchymal rejection and reduced allograft survival; in contrast, adoptive transfer of WT neutrophils did not affect graft survival. Mac-1−/− macrophages expressed significantly lower levels of costimulatory molecules both in vivo and in vitro, and mixed lymphocyte reaction using alloantigen-primed Mac-1−/− macrophages resulted in significantly lower antigen-presenting function than for WT macrophages. Tumor necrosis factor-α production also fell in cultures with Mac-1−/− macrophages. Despite attenuation of acute rejection, recipient Mac-1-deficiency did not prevent late graft arterial disease.

Conclusions—These studies demonstrate critical participation of Mac-1 in alloresponses during cellular allograft rejection. These observations establish a molecular target for modulating recipient responses to prolong graft survival.

(Circulation. 2008;117:1997-2008.)

Key Words: antigen-presenting cells ■ immunology ■ macrophage-1 antigen ■ pathogenesis ■ rejection ■ transplantation

Clinical Perspective p 2008

Formation of the immunological synapse requires direct interaction between T-cell integrins and cognate ligands on antigen-presenting cells (APCs).2 LFA-1 binding to intracellular adhesion molecule-1 (ICAM-1) reduces the level of antigen required to form the immune synapse, thereby lowering B-cell activation thresholds.3 Engagement of ICAM-1 on target cells leads to major histocompatibility complex class I (MHC-I) recruitment to contact areas and enhances presentation of cognate peptide/MHC-I complexes to cytotoxic T cells.4

Mac-1 resides on neutrophils, monocytes, macrophages, dendritic cells, CD8+ T cells, and natural killer cells.5-7

Received June 28, 2007; accepted February 13, 2008.
From the Donald W. Reynolds Cardiovascular Clinical Research Center, Cardiovascular Division, Department of Medicine (K.S., P.L., R.S.) and Department of Pathology (K.A., R.N.M.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass, and Division of Cardiovascular Medicine, University Hospitals of Cleveland—Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (M.S., Y.W., D.I.S.).
Guest Editor for this article was Gilbert R. Upchurch, MD.
*Dr Mitchell and Dr Simon contributed equally to this article.
Correspondence to Koichi Shimizu, MD, PhD, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, 77 Ave Louis Pasteur, NB7, Boston, MA 02115. E-mail ksmz@rics.bwh.harvard.edu
© 2008 American Heart Association, Inc.

Circulation is available at http://circ.ahajournals.org

DOI: 10.1161/CIRCULATIONAHA.107.724310

1997
Endothelial ligands for Mac-1 include ICAM-1,8–10 endothelial-associated extracellular matrix proteins (eg, fibronogen),11–13 CD154,14 and glycosaminoglycans.15 These adhesive interactions facilitate firm attachment and transmigration into interstitial tissue.16,17

Numerous studies have shown that the donor ECs in rejecting cardiac allografts robustly express ICAM-1 and that augmented expression of adhesion molecules precedes leukocyte accumulation within vessels.18–20 These results suggest that ICAM-1 induction during early rejection contributes to mononuclear cell recruitment and renders ECs more susceptible to cell-mediated injury, including graft arterial disease (GAD).20,21 Nevertheless, it remains unclear whether donor adhesion molecules contribute critically to allograft rejection. Treatment with monoclonal antibodies against ICAM-1 and LFA-1 resulted in indefinite cardiac allograft survival between fully histoincompatible mice strains22 but had no effect on allograft survival in fully incompatible rat strains.23 In 1 study, ICAM-1–deficient donor hearts did not exhibit prolonged graft survival or attenuated GAD;24 in another report, ICAM-1–deficient donor hearts had modest (2 to 2.5 days), albeit significantly prolonged, graft survival.25

A definitive role for Mac-1 in allograft rejection is uncertain. Antibody targeting of Mac-1 did not affect graft survival time but decreased the accumulation of graft macrophages.26 However, antibody experiments have several important limitations: (1) Complete blockade is difficult, particularly for those integrins with mobilizable intracellular storage pools such as Mac-1;27 (2) antibodies binding to the surface of leukocytes can stimulate changes in cellular functions and behavior (eg, through activation of Fc receptors when immunoglobulin G [IgG] antibodies are used); and (3) because Mac-1 associates closely with and influences other cell surface receptors such as the urokinase receptor,28 antibody binding may cause steric interference with the associated receptor. The present study avoided these limitations of antibody administration by using a genetic approach, examining parenchymal rejection (PR) and GAD after cardiac transplantation in Mac-1–/– recipients.

**Methods**

**Animals**

C57BL/6 (B6; H-2b), B6.C-H2<bm12>/KbEg (bm12; H-2<bm12>), and BALB/c (B/c) mice were from Taconic Farms (Germantown, NY) or The Jackson Laboratory (Bar Harbor, Me). Mac-1–/– C57BL/6 mice were kindly provided by Dr Christie M. Ballantyne (Baylor College of Medicine, Houston, Tex).29 Mice were maintained on acidified water in barrier animal facilities. Animal care and procedures were reviewed and approved by the Harvard Medical School Standing Committee on Animals and performed in accordance with the guidelines of the American Association for Accreditation of Laboratory Animal Care and the National Institutes of Health.

**Vascularized Heterotopic Cardiac Transplantation**

B/c (total allomismatch to assess effects on acute rejection) or bm12 (MHC-II mismatch to assess effects on GAD) donor hearts were transplanted heterotopically into B6 recipients without immunosuppression.30 We assessed graft function by palpation twice daily. In total allomismatched experiments, 2 cohorts of wild-type (WT) and Mac-1–/– recipients were used. The first group of animals served to determine graft survival, defined as the day of cessation of beating or when the strength of beating declined to the point that failure would occur (by prior experience) within the next 12 hours. In the second group of animals, beating cardiac allografts were harvested at the prespecified time point of 7 days after transplantation. For single MHC-II–mismatched transplantation, grafts were harvested at 4 and 12 weeks.

PR and the severity and extent of GAD were quantified with a 4-point scoring system by blinded observers as described previously.30 PR was scored on a scale of 0 to 4 (0, no rejection; 1, focal mononuclear cell infiltrates; 2, focal mononuclear infiltrates with necrosis; 3, multifocal infiltrates with necrosis; and 4, widespread infiltrates with hemorrhage and/or vasculitis); GAD was scored on a scale of 0 to 4 on the basis of the extent of luminal stenoses averaged over ≥10 arteries (0, <10%; 1, 10% to 25%; 2, 25% to 50%; 3, 50% to 75%; and 4, >75% stenosis).

**Graft Harvest**

Harvested allografts were transversely sectioned into 3 parts. In sectioned hearts, the most basal part was used for routine hematoxylin and eosin morphological examination. A second midtransverse section was fixed for immunohistochemical staining, and the apical portion was used for total RNA extraction for RNase protection assay.30 For cellular extraction, hearts were digested at 37°C in 2 mg/mL collagenase (Sigma, St Louis, Mo) and 2% BSA in buffered saline, followed by straining and Ficoll density gradient centrifugation (Organon Teknika, West Chester, Pa).30

**Immunohistochemistry**

Cryosections (5 μm) were fixed in acetone before incubation with 0.5% H2O2. Slides were incubated with 10% normal goat serum and stained with purified monoclonal anti-CD4 (RM4-5), anti-CD8 (53-6.7), anti–Mac-3 (macrophage), or anti–Gr-1 (neutrophil, RB6-8C5) antibodies. Sections were incubated with biotinylated goat anti-rat IgG antibodies (1 μg/mL, Southern Biotechnology Associates, Inc, Birmingham, Ala), followed by streptavidin-peroxidase (Dako, Glostrup, Denmark). Antibody binding was visualized with 3-amino-9-ethyl carbazole (Dako). Nuclei were counterstained with Gill’s hematoxylin (Sigma).

**Mixed Lymphocyte Reaction, T-Cell Proliferation Assay, and Cytokine ELISA**

One-way mixed lymphocyte reaction (MLR) was performed as described previously30 with irradiated B6 splenocytes as stimulators and B6 splenocytes as responders. T-cell or B-cell proliferation assay was performed with anti-CD3 antibody-coated 96-well plates or by adding anti-CD40 monoclonal antibodies (3/23, BD PharMingen, San Diego, Calif).

We also performed MLR using allograft-derived macrophages as stimulators and naive B6 T cells as responders. We isolated macrophages from the allografts of B6 WT or B6 Mac-1–/– recipients 7 days after transplantation as described previously.30 We extracted T cells from naive B6 WT splenocytes using MACS beads (Miltenyi Biotec Inc, Auburn, Calif) with negative selection according to the manufacturer’s methods. We plated irradiated allograft-derived macrophages (50,000 cells per well) and naive B6 T cells (500 000 cells per well, S:R=1:10) in the 96-well plates and measured T-cell proliferation using H-3-thymidine incorporation.30 We also measured tumor necrosis factor-α (TNF-α) levels in the supernatant of the coculture by ELISA as described previously30 using purified anti–TNF-α and biotinylated anti–TNF-α monoclonal antibodies (BD PharMingen).

**Total RNA Extraction and RNase Protection Assay**

Total RNA was isolated from allografts with the TRIzol reagent (Invitrogen, Carlsbad, Calif). RNase protection assay was performed (RiboQuant, PharMingen) with 10 μg RNA from each heart according to the manufacturer’s recommendations.
Murine Peritoneal Macrophage and Bone Marrow Neutrophil Isolation
Peritoneal cells were collected via peritoneal lavage using 10 mL ice-cold RPMI 1640. Lavage cells were pelleted, resuspended in 5 mL hypertonc RBC lysis buffer (ACK lysis buffer, InVitrogen) at 37°C for 5 minutes, washed with RPMI 1640 twice, and resuspended in 5 mL RPMI 1640. Cells were centrifuged in Percoll gradient solution for 30 minutes. Cells in the upper layer were resuspended in 10% FCS RPMI 1640, plated on plastic dishes for 60 minutes, and washed twice to remove nonadherent cells, resulting in >95% pure macrophages, confirmed by Mac-3 staining and flow cytometry. To isolate neutrophils from the bone marrow, we removed the femur and tibia from both hind legs and cut off the extreme distal tip of each extremity. RPMI 1640 medium was forced through the bone with a syringe. After dispersing cell clumps and erytholysis, the cell suspension was centrifuged (400g for 10 minutes at 4°C) and resuspended in 1 mL RPMI 1640. Cells were then treated on a 3-layer Percoll gradient exactly as described above for peritoneal cells. Flow cytometry using anti-Ly-6G and Gr-1 antibodies showed >95% purity of neutrophils.

Murine EC Isolation and Coculture
With Macrophages
ECs were isolated from the B/c murine hearts as described previously and incubated for 72 hours with the peritoneal macrophages extracted from naive B6 WT or Mac-1−/− mice. We performed flow cytometry analysis for costimulatory molecule expression of the B/c EC-primed macrophages as described below.

Cellular Surface Staining and Flow Cytometric Analysis
Graft-infiltrating cells and B/c-EC-primed macrophages were analyzed by flow cytometry after surface staining using methods described previously. Antibodies included anti–MHC-II phycoerythrin (PE) (I-A/E, M5/114.15.2), anti–CD40-PE, anti–CD86-PE, or anti–ICOSL-PE antibodies; PE-conjugated rat IgG2b (negative control, PharMingen); or anti–CD80-PE and PE-conjugated hamster IgG (negative control). Anti–MAC-3 antibody was used for macrophage staining.

Statistical Analysis of the Graft Survival and Cell Number, Proliferation, and Cytokine Production
Comparisons between the 2 groups for graft survival used Kaplan–Meier and log-rank tests; frequency of graft-infiltrating cells, cell proliferation, and ELISA used 1-way ANOVA. We described PR and GAD scores as mean±SD and analyzed them by Fisher exact test using the GraphPad Prism 4 software for Macintosh (GraphPad Software, San Diego, Calif).

Results
Deficiency of Recipient Mac-1 Attenuates PR and Prolongs Graft Survival in Total Allomismatched Allografts
In total allomismatched murine cardiac allografts (B/c donor hearts and B6 recipients), survival averaged 13.8±2.3 days (mean±SD; n=6) for allografts in Mac-1−/− recipients compared with 8.2±1.3 days (n=18) in WT recipients (Figure 1A). Failing grafts in WT recipients showed severe coronary arteritis with perivascular edema and confluent areas of myocardial necrosis 7 days after transplantation. In comparison, at the same time point, grafts in Mac-1−/− recipients exhibited virtually no arterial inflammation, edema, or coagulative necrosis, despite the presence of multifocal parenchymal inflammatory infiltrates (Figure 1B). Reflecting these differences, the PR scores were significantly lower for allografts in Mac-1−/− recipients 7 days after transplantation (2.3±0.4, mean±SD; n=6) compared with WT recipients (3.0±0.4; n=13; P=0.0408). At this 7-day time point, inflammatory cells and thrombi populated vessel luminal areas in allografts of WT recipients. These lesions differ from chronic GAD lesions that consist predominantly of smooth muscle–like cells. Nevertheless, we scored the extent of early luminal occlusion using the GAD scoring system. Scores were significantly lower for grafts in Mac-1−/− (0.01±0.02, mean±SD; n=6) compared with WT (0.63±0.44; n=13; P=0.0108) recipients (Figure 1C). Thus, deficiency of recipient Mac-1 prolongs allograft survival and is associated with diminished inflammatory cell accumulation, including reduced luminal inflammatory cells. At the time of eventual graft failure in Mac-1−/− recipients (13.8±2.3 days), PR scores were 3.2±0.9, with luminal stenosis graded at 1.3±1.1.

Mac-1 Deficiency Reduces the Intragraft Accumulation of Neutrophils, CD8+ T Lymphocytes, and Macrophages
Immunohistochemical analysis examined the characteristics of the immune cell infiltration in transplanted hearts in WT and Mac-1−/− recipients 7 days after allografting. Anti–Gr-1 identified neutrophils, anti–CD4 or anti–CD8 for T cells, and anti–Mac-3 for macrophages. Neutrophil (Gr-1–positive cells), CD8+ T cell, and macrophage (Mac-3–positive cells) accumulation all decreased significantly in Mac-1−/− compared with WT recipients. The transplanted hearts of both Mac-1−/− and WT recipients had comparable numbers of CD4+ T cells (Figure 2A and 2B). To verify that differences in leukocyte recruitment in Mac-1−/− mice were not secondary to differences in peripheral blood leukocyte counts, we performed complete blood cell count analysis in WT and Mac-1−/− mice. No statistical differences were found in the number of peripheral blood neutrophils (2.12±0.67 versus 2.10±0.53×107/μL; mean±SD; P=0.96), monocytes (0.11±0.06 versus 0.09±0.04×107/μL; P=0.53), and lymphocytes (6.85±0.67 versus 6.52±0.28; P=0.40) between WT (n=4) and Mac-1−/− (n=4), respectively.

WT Macrophage but Not Neutrophil Adoptive Transfer Reduces Allograft Survival in Mac-1−/− Recipients
Both neutrophils and monocytes/macrophages can participate in acute graft failure. Deficiency of Mac-1 reduces the recruitment of both neutrophils and monocytes/macrophages at sites of vascular injury. To determine the cell type involved in acute graft dysfunction, we performed an adoptive transfer experiment using neutrophils and macrophages from WT donors. Mac-1−/− recipients of B/c heart allografts were injected intravenously with either neutrophils (5×106) or macrophages (5×105) extracted from WT or Mac-1−/− mice 1 day after transplantation. Neither WT nor Mac-1−/− neutrophil adoptive transfer affected graft survival in Mac-1−/− recipients (Figure 3A). However, adoptive transfer of WT but not Mac-1−/− macrophages significantly reduced
graft survival of Mac-1<sup>−/−</sup> recipients (Figure 3B). PR scores of allografts also increased significantly in Mac-1<sup>−/−</sup> recipients receiving WT (2.3±0.4; mean±SD; n=6) versus Mac-1<sup>−/−</sup> (1.5±0.5; n=5; \( P=0.024 \)) macrophages (Figure 3C). These observations indicate that macrophages expressing Mac-1 participate in graft inflammatory cell accumulation and influence graft survival in total allomismatched allografts.

**Lack of Mac-1 Reduced Early PR and GAD but Not Chronic GAD in MHC-II–Mismatched Cardiac Transplantations**

We examined PR and GAD after MHC-II–mismatched murine heart transplantation using bm12 donor hearts and WT or Mac-1<sup>−/−</sup> B6 recipients without immunosuppression. Single MHC class mismatch permits graft survival for the assessment of GAD. Grafts were harvested at 4 and 12 weeks after transplantation. The 12-week time point is commonly used to evaluate arterial lesions at a more chronic stage when GAD lesions typically are well developed.<sup>12,15</sup> Four weeks after transplantation, both PR (Mac-1<sup>−/−</sup>, 1.9±0.5 [n=6] versus WT, 2.8±0.8 [n=8]; \( P=0.026 \)) and GAD (Mac-1<sup>−/−</sup>, 0.0±0.0 [n=6] versus WT, 1.2±1.1 [n=8]; \( P=0.031 \)) scores were reduced in Mac-1<sup>−/−</sup> compared with WT recipients. However, at 12 weeks, GAD lesions were comparable in Mac-1<sup>−/−</sup> (1.7±1.1; n=8) and WT (2.2±1.5; n=11; \( P=0.65 \)) recipients (Figure 4). PR at 12 weeks was reduced compared with 4 weeks but was similar in Mac-1<sup>−/−</sup> (1.5±1.1) and WT (2.0±1.0; \( P=0.63 \)) recipients.

![Figure 1. Recipient Mac-1 deficiency attenuates acute PR and prolongs graft survival after total allomismatched transplantation. A, Kaplan–Meier analysis of graft survival after total allomismatched heart transplantation in WT (n=18) and Mac-1<sup>−/−</sup> (n=6) recipients. B, Photomicrographs of B/c cardiac allografts harvested 7 days after transplantation in WT and Mac-1<sup>−/−</sup> B6 recipients: hematoxylin and eosin staining (a and b), Masson’s trichrome staining (c and d), PR (e) and luminal occlusion (f) scores (mean±SD) were determined as described in Methods from hearts harvested from WT (solid bars; n=13) and Mac-1<sup>−/−</sup> (open bars; n=6) recipients.](http://circ.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.705318)
Chemokine mRNA Expression Is Comparable in Allografts From WT and Mac-1−/− Recipients

The reduction in graft immune cell infiltration in Mac-1−/− recipients could result from diminished EC adhesion via leukocyte Mac-1 or from changes in local chemokine and cytokine expression. To test the latter possibility, we performed RNase protection assay to measure chemokine and cytokine mRNA expression from allografts harvested 7 days after transplantation. Allograft expression of regulated on activation, normal T cell expressed and secreted (RANTES), monocyte chemotactic protein-1, macrophage inflammatory protein (MIP)-1α, MIP-1β, MIP-2, and IFN-inducible protein 10 mRNA was similar in WT and Mac-1−/− recipients. Among cytokine mRNA expression profiles, only TNF-α decreased significantly in Mac-1−/− compared with WT recipients (Figure 5).

Mac-1−/− Splenocytes Have Attenuated MLR but Normal Responses to Anti-CD3 and Anti-CD40 Antibodies

Interaction of APCs and T cells, as well as the subsequent strength of the alloresponse, may affect cellular recruitment.36 Mac-1 also can directly limit T-cell and/or dendritic cell function and may alter the local cytokine milieu.5,6,37 Therefore, we examined whether Mac-1 deficiency modulates MLR using WT or Mac-1−/− splenocytes as responders and irradiated B/c splenocytes as stimulator cells. Mac-1−/− splenocytes showed significantly less proliferation compared with WT splenocytes after 3 to 5 days of culture (Figure 6A). To dissect the mechanisms by which Mac-1−/− splenocytes show defective proliferative responses, we stimulated splenocytes with anti-CD3 monoclonal antibodies (ie, direct T-cell stimulation) or anti-CD40 (3/23) monoclonal antibodies (direct B-cell stimulation). Interestingly, both WT and Mac-1−/−
splenocytes proliferated comparably under these conditions (Figure 6B and 6C), suggesting that Mac-1–deficient T and B cells have normal intrinsic proliferative capability. The results indicate that Mac-1⁻⁻ splenocytes have attenuated antigen-presenting functions.

To examine whether Mac-1–deficient splenocytes ineffectively prime T cells, we performed B/c-primed MLR. B/c-primed splenocytes from WT or Mac-1⁻⁻ recipients of B/c cardiac allografts were recovered 6 days after transplantation and were stimulated with or without (control) irradiated naive B/c splenocytes. Interestingly, splenocytes harvested from Mac-1⁻⁻ transplant recipients showed significantly less proliferation compared with splenocytes recovered from WT recipients (Figure 6D). The results suggest that Mac-1⁻⁻ splenocytes lead to ineffective T-cell priming in vivo.

**Mac-1⁻⁻ Macrophages Express Reduced Levels of Costimulatory Molecules and Have Diminished Alloantigen-Presenting Function**

Macrophages make up most of inflammatory cells at the later phases of acute rejection.³⁰,³⁸ Macrophages can exhibit direct cytotoxicity against certain cells³⁹ and can function in allograft rejection as APCs.⁴⁰ We tested the hypothesis that intragraft Mac-1⁻⁻ macrophages have impaired activation and exhibit reduced antigen-presenting function compared with WT macrophages. To do so, immune cells were extracted from cardiac allografts harvested from WT and Mac-1⁻⁻ recipients 6 days after transplantation; flow cytometry was performed to assess macrophage MHC-II and costimulatory molecule expression. Graft macrophages in Mac-1⁻⁻ recipients showed significantly lower expression of CD40, CD80, CD86, ICOSL, and MHC-II compared with those in WT recipients (Figure 7A and 7B).

We also used the macrophages extracted from B/c allografts of B6 WT or Mac-1⁻⁻ recipients as a stimulator of B6 naive T cells and performed primed MLR (primed macrophages as stimulator and naive T cells as responder). The results demonstrated that naive T cells stimulated by the primed macrophages extracted from the allografts of Mac-1⁻⁻ recipients had a lower proliferative capacity (Figure 7C) and secreted less TNF-α (Figure 7D) compared with those stimulated by the primed macrophages extracted from the allografts of WT recipients. These results suggested that Mac-1⁻⁻ macrophages have lower antigen-presenting capacity.

Because recipient leukocytes first encounter donor ECs after transplantation, the ability of donor ECs to facilitate antigen presentation probably is important. Thus, to assess
whether macrophages (B6) can process and present a foreign antigen of the ECs (B/c) in vitro, we performed B/c-EC and B6-macrophage coculture and examined the antigen-presenting capacity of the macrophages to B6 T cells. Naive B6 peritoneal macrophages also were extracted from WT and Mac-1/H11002/H11002/B6 animals and cocultured with B/c ECs. After 3 days, macrophages were isolated by gradient centrifugation and used for flow cytometry analysis. Mac-1/H11002/H11002/H11002/macrophages expressed significantly lower levels of CD40 (mean fluorescence intensity, 22.7±4.5) and CD86 (71.7±9.5) compared with WT macrophages (CD40, 87.7±21.3, P=0.0016, n=4; CD86, 150±18.2, P=0.0089, n=4) (Figure 7E). Of note, no significant differences occurred in the expression (mean SD fluorescence intensity) of CD40 (Mac-1/H11002/H11002/H11002, 19.8±5.9 versus WT, 20.0±7.0; P=0.96), CD80 (20.8±10.4 versus 22.8±7.5; P=0.77), CD86 (48.3±14.9 versus 50.5±24.0; P=0.77), and ICOSL (15.0±6.5 versus 13.5±5.1; P=0.73) on naive peritoneal macrophages isolated from Mac-1/H11002/H11002/H11002 recipients, compared with WT mice. These findings indicate that Mac-1/H11002/H11002/H11002 macrophages cocultured with B/c ECs have weaker antigen-presenting capacity than WT macrophages.

**Discussion**

The present study provides in vivo evidence that Mac-1 promotes acute allograft rejection. Recipient Mac-1 deficiency reduced allograft accumulation of immune cells, prolonged allograft survival, but did not prevent GAD. The
results demonstrated an important role for Mac-1 in macrophage antigen presentation by showing that Mac-1⁻/⁻ macrophages expressed significantly lower levels of the costimulatory molecules both in vivo and in vitro and that MLR using alloprimed Mac-1⁻/⁻ macrophages resulted in significantly lower antigen-presenting function than WT macrophages. Furthermore, WT but not Mac-1⁻/⁻ macrophage adoptive transfer to Mac-1⁻/⁻ recipients exacerbated PR and reduced allograft survival. In comparison, adoptive transfer of WT neutrophils did not affect graft survival. We also have observed that blockade of neutrophil recruitment with anti-Gr1 antibody (RB6-8C5) treatment does not prevent acute rejection (K.S., unpublished data, 2004).

Possible Mechanism of Mac-1 Action in Acute Rejection
Mac-1 localizes on neutrophils, monocytes, macrophages, natural killer cells, and CD8⁺ T cells. The functional relevance of β₂-integrins such as Mac-1 (CD11b/CD18) on APCs remains unclear. Varga and coworkers reported recently that Mac-1 on APCs, including dendritic cells and macrophages, directly inhibited T-cell activation. In that study, CD18⁻/⁻ macrophages stimulate allogeneic T cells more potently than their WT counterparts. However, Mac-1⁻/⁻ (CD11b⁻/⁻) APCs were not examined, thereby precluding definitive conclusions on the precise role of Mac-1 given the possible contributions of other β₂-integrins, including...
Figure 7. Mac-1$^{-/-}$ macrophages have diminished APC function. A, Representative figure shows expression of costimulatory molecules and MHC-II (solid graph) on macrophages extracted from day 7 transplanted cardiac allografts in Mac-1$^{-/-}$ (top) and WT (bottom) recipients assessed by flow cytometry and double staining with PE-conjugated anti-CD40, anti-CD80, anti-CD86, anti-ICOSL, or anti-MHC-II (IA/IE) and FITC-conjugated anti-Mac-3. Clear graph shows negative control using PE-conjugated rat immunoglobulin G2a (IgG2a; negative control for CD40, CD86, ICOSL, and MHC-II) or hamster IgG (negative control for CD80). B, Bar graph shows values representing mean±SEM fluorescent intensity (MFI) of the Mac-3 macrophages extracted from WT (solid bars) and Mac-1$^{-/-}$ (open bars) recipient allografts (n=4 per group). C and D, Proliferation of naive wild-type B6 T cells stimulated by the macrophages extracted from B/c allografts of B6 WT (solid bars) and Mac-1$^{-/-}$ (open bars) recipients (C) and production of TNF-α from those T cells (D) were assessed as described in Methods. Macrophage antigen presentation after interaction with allogeneic ECs. E, Expression of costimulatory molecules on B/c EC-primed WT (solid) and Mac-1$^{-/-}$ (open) macrophages was assessed by flow cytometry as described above. Data represent average values (mean±SEM) of 3 independent experiments (n=4 per group).
indicating that Mac-1
mononuclear
urn-dependent mononuclear cell recruitment mediated by
injury involving intact, activated endothelium (ie, endotheli-
compared with the pathways downstream of immunological
macrophages in Mac-1
oxidative burst, and signaling.29,31,49–52
adhesion, migration, coagulation, proteolysis, phagocytosis,
tant leukocyte functions relevant to vascular injury, including
CD154,14 and JAM-3,48 Mac-1 potentially regulates impor-
By virtue of binding diverse ligands such as fibrinogen,42,43
ICAM-1,14 factor X,45 C3bi,42 platelet glycoprotein Ibα,46,47
CD154,14 and JAM-3,48 Mac-1 potentially regulates import-
Our prior report identified Mac-1 as a molecular determi-
neointimal thickening after endothelium-denuding
injury; selective absence of Mac-1 impaired transplatelet
leukocyte migration into the vessel wall, diminishing medial
leukocyte accumulation and neointimal thickening after ex-
perimental angioplasty.34 In the present study, deficiency of
Mac-1 attenuated allograft leukocyte accumulation and rejec-
tion but had no effect on neointimal thickening in GAD at 12
weeks. These discrepant effects on neointimal thickening
likely reflect a distinct cell recruitment mechanism provoked
by mechanical arterial injury (ie, platelet-dependent neutro-
phil recruitment mediated in part by integrin interactions
between neutrophil Mac-1 and platelet glycoprotein Ibα
compared with the pathways downstream of immunological
injury involving intact, activated endothelium (ie, endotheli-
un-dependent mononuclear cell recruitment mediated by
mononuclear β1- and β2-integrins and endothelial ICAM-1
and vascular cell adhesion molecule-1). Similar to GAD,
deficiency of Mac-1 has no effect on high-fat-diet–induced
atherosclerotic lesion formation in low-density lipoprotein
receptor–deficient mice.53
Clinical Implications
Allograft rejection, both cellular and antibody mediated,
remains a clinically important limitation to human cardiac
transplantation. More than 40% of patients will experience an
episode of rejection in the first year after transplant that
requires therapy; the average patient will experience close to
2 episodes of rejection in the first year.54 Severe rejection
episodes can cause heart failure, malignant arrhythmias, and
sudden cardiac death. Higher grades of rejection (International
Society for Heart and Lung Transplantation grade 3 or 4)
portend poor outcomes.54 Current treatment strategies
often resolve the acute episode effectively and typically
include the use of augmented doses of glucocorticoids or
calcineurin inhibitors, cytolytic agents such as OKT3, and
plasmapheresis. However, they are limited by the inherent
toxicities of immunosuppression, including fatal infections,
aggressive malignancies, and renal failure. Furthermore,
antibody-mediated rejection, in particular, has no consensus
treatment to date.55 Novel therapies are greatly needed not
only to decrease the morbidity of conventional immunosup-
pression but also to improve the outcomes of patients with
specific forms of allograft rejection, especially acute
antibody-mediated rejection. Although deficiency of Mac-1
did not prevent chronic rejection in our study, targeting
Mac-1 is an attractive strategy to modulate acute rejection
after cardiac transplantation. Indeed, previous clinical trials
demonstrated improved renal allograft survival in high-risk
patients (either highly immunized or retransplant recipients)
who received a monoclonal antibody to one of the Mac-1
cognate ligands, ICAM-1.56
Study Limitations
We examined the effect of Mac-1 deficiency on PR and GAD
after MHC-II–mismatched murine heart transplantation with-
out background immunosuppression. Clinical application re-
quires future studies evaluating the effect of Mac-1 defi-
ciency and immunosuppressive therapy, alone or in
combination, on rejection scores and GAD.
Mac-1 deficiency may affect the development and function of
immune cells. The present experiments using adoptive
transfer of normal cells provide compelling evidence for the
importance of macrophage Mac-1 in acute rejection. None-
theless, we cannot rule out an additional role of Mac-1 in the
development and function of immune cells.
Conclusion
This study demonstrates that recipient Mac-1 deficiency
reduces accumulation of graft-infiltrating cells, macrophage
APC function, T-cell proliferation, and TNF-α production
and attenuates acute allograft rejection.
Acknowledgments
We thank D. Cameron, E. Shvartz, J.N. Vaisviliene, M. Rodrigue, G.
Suliman, and E. Simon-Morrissey for their technical expertise and J.
Perry for editorial assistance.
Sources of Funding
This work was supported by an American Heart Association Scien-
tist Development grant (Dr Shimizu), a grant award from the Roche
Organ Transplantation Research Foundation (Dr Shimizu), a Har-
vard Medical School BWH Fellowship Award (Dr Shimizu), and
grants from the Donald W. Reynolds Foundation (Dr Libby) and the
National Institutes of Health (HL-43364 to Drs Libby and Mitchell;
GM-67049 to Drs Mitchell, Shimizu, and Libby; HL-67249 to Drs
Shimizu and Mitchell; HL-67283 to Dr Shimizu; HL-34636 to Dr
Libby; and HL57056 and HL60942 to Dr Simon).
Disclosures
None.
References
1. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte
Shimizu et al. Mac-1 and Cardiac Allograft Survival


CLINICAL PERSPECTIVE

Allograft rejection remains a clinically important limitation to human cardiac transplantation. More than 40% of patients will experience an episode of rejection that requires therapy in the first year after transplantation. Severe rejection episodes can cause heart failure, malignant arrhythmias, and sudden cardiac death. Higher grades of rejection (International Society for Heart and Lung Transplantation grade 3 or 4) portend poor outcomes. Current treatment strategies often resolve the acute episode effectively and typically include the use of augmented doses of glucocorticoids or calcineurin inhibitors, cytolytic agents such as OKT3, and plasmapheresis. However, they are limited by the inherent toxicities of immunosuppression, including fatal infections, aggressive malignancies, and renal failure. Furthermore, antibody-mediated rejection, in particular, has no consensus treatment to date. Novel therapies are greatly needed not only to decrease the morbidity of conventional immunosuppression but also to improve the outcomes of patients with specific forms of allograft rejection, especially acute antibody-mediated rejection. Although deficiency of Mac-1 did not prevent chronic rejection in our study, targeting Mac-1 is an attractive strategy to modulate acute rejection after cardiac transplantation. Indeed, previous clinical trials demonstrated improved renal allograft survival in high-risk patients (either highly immunized or retransplant recipients) who received a monoclonal antibody to one of the Mac-1 cognate ligands, intracellular adhesion molecule-1. This study demonstrates that recipient Mac-1 deficiency reduces accumulation of graft-infiltrating cells, macrophage antigen-presenting cell function, T-cell proliferation, and tumor necrosis factor-α production and attenuates acute allograft rejection. Clinical application requires future studies evaluating the effect of Mac-1 deficiency and immunosuppressive therapy, alone or in combination, on allograft rejection.